These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 15054715)

  • 21. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results.
    Rose JW; Burns JB; Bjorklund J; Klein J; Watt HE; Carlson NG
    Neurology; 2007 Aug; 69(8):785-9. PubMed ID: 17709711
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Natural history of multiple sclerosis: a unifying concept.
    Confavreux C; Vukusic S
    Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New natural history of interferon-beta-treated relapsing multiple sclerosis.
    Trojano M; Pellegrini F; Fuiani A; Paolicelli D; Zipoli V; Zimatore GB; Di Monte E; Portaccio E; Lepore V; Livrea P; Amato MP
    Ann Neurol; 2007 Apr; 61(4):300-6. PubMed ID: 17444502
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuropsychological testing and event-related potentials in the assessment of cognitive performance in the patients with multiple sclerosis--a pilot study.
    Pokryszko-Dragan A; Zagrajek M; Slotwinski K; Gruszka E; Bilinska M; Podemski R
    Clin Neurol Neurosurg; 2009 Jul; 111(6):503-6. PubMed ID: 19233546
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Physiological measures of therapeutic response to interferon beta-1a treatment in remitting-relapsing MS.
    White AT; Petajan JH
    Clin Neurophysiol; 2004 Oct; 115(10):2364-71. PubMed ID: 15351379
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Functionality or aesthetics? A pilot study of music therapy in the treatment of multiple sclerosis patients.
    Aldridge D; Schmid W; Kaeder M; Schmidt C; Ostermann T
    Complement Ther Med; 2005 Mar; 13(1):25-33. PubMed ID: 15907675
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
    Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Cognitive evoked potentials in remitting-relapsing and benign forms of multiple sclerosis].
    Vázquez-Marrufo M; González-Rosa J; Vaquero-Casares E; Duque P; Borges M; Izquierdo G
    Rev Neurol; 2009 May 1-15; 48(9):453-8. PubMed ID: 19396761
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Neuropsychological assessment of patients with relapsing remitting multiple sclerosis prior to the use of immunomodulatory drugs].
    Nogales-Gaete J; Aracena R; Díaz V; Zitko P; Eloiza C; Cepeda-Zumaeta S; Agurto P; González C
    Rev Med Chil; 2012 Nov; 140(11):1437-44. PubMed ID: 23677190
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brain damage as detected by magnetization transfer imaging is less pronounced in benign than in early relapsing multiple sclerosis.
    De Stefano N; Battaglini M; Stromillo ML; Zipoli V; Bartolozzi ML; Guidi L; Siracusa G; Portaccio E; Giorgio A; Sorbi S; Federico A; Amato MP
    Brain; 2006 Aug; 129(Pt 8):2008-16. PubMed ID: 16815879
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of neocortical volume changes with cognitive deterioration in relapsing-remitting multiple sclerosis.
    Amato MP; Portaccio E; Goretti B; Zipoli V; Battaglini M; Bartolozzi ML; Stromillo ML; Guidi L; Siracusa G; Sorbi S; Federico A; De Stefano N
    Arch Neurol; 2007 Aug; 64(8):1157-61. PubMed ID: 17698706
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cognitive impairment in newly diagnosed multiple sclerosis patients: a 4-year follow-up study.
    Jønsson A; Andresen J; Storr L; Tscherning T; Soelberg Sørensen P; Ravnborg M
    J Neurol Sci; 2006 Jun; 245(1-2):77-85. PubMed ID: 16647089
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Predicting factors for depression in multiple sclerosis].
    Alarcia R; Ara JR; Martín J; Bertol V
    Neurologia; 2004 Sep; 19(7):364-8. PubMed ID: 15273883
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical features of 314 patients with relapsing-remitting multiple sclerosis].
    Nogales-Gaete J; Aracena R; Cepeda-Zumaeta S; Eloiza C; Agurto P; Díaz V; Labbé S; Martínez S; Flores J; Araya C
    Rev Med Chil; 2014 May; 142(5):559-66. PubMed ID: 25427011
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Social anxiety in a multiple sclerosis clinic population.
    Poder K; Ghatavi K; Fisk JD; Campbell TL; Kisely S; Sarty I; Stadnyk K; Bhan V
    Mult Scler; 2009 Mar; 15(3):393-8. PubMed ID: 19028833
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis.
    Etemadifar M; Janghorbani M; Shaygannejad V
    Acta Neurol Scand; 2006 May; 113(5):283-7. PubMed ID: 16629762
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cognitive dysfunction evaluation in multiple sclerosis patients treated with interferon beta-1b: an open-label prospective 1 year study.
    Flechter S; Vardi J; Finkelstein Y; Pollak L
    Isr Med Assoc J; 2007 Jun; 9(6):457-9. PubMed ID: 17642394
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multimodal evoked potentials measure and predict disability progression in early relapsing-remitting multiple sclerosis.
    Jung P; Beyerle A; Ziemann U
    Mult Scler; 2008 May; 14(4):553-6. PubMed ID: 18562509
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Personality features in multiple sclerosis patients with a relapsing-remitting course of the disease].
    Papuć E; Pawłowska B
    Psychiatr Pol; 2005; 39(4):669-78. PubMed ID: 16237972
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of education level and employment status on HRQoL in early relapsing-remitting multiple sclerosis.
    Patti F; Pozzilli C; Montanari E; Pappalardo A; Piazza L; Levi A; Onesti E; Pesci I;
    Mult Scler; 2007 Jul; 13(6):783-91. PubMed ID: 17613607
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.